What's new
This page lists items that we have published for the first time or updated in the last 7, 30 or 60 days. Use the filters to narrow results by audience, product type, content type or topic.
You can also stay informed by:
- subscribing to our updates to receive same-day notification emails on safety information, scheduling updates or media releases.
- checking our consultation hub.
- joining any upcoming events.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (17)
- Clinical trials (1)
- Committees and advisory bodies (4)
- Compliance and enforcement (20)
- Cosmetics (3)
- Fees and payments (4)
- Import and export (7)
- Labelling and packaging (3)
- Legislation (3)
- Manufacturing (6)
- Safety monitoring and information (13)
- Scheduling (national classification system) (3)
- Shortages and supply disruptions (11)
- Unique Device Identification (UDI) hub (19)
- Vaping hub (1)
- Weight loss products (1)
What's new
122 result(s) found, displaying 76 to 100
-
PageUnderstand if Unique Device Identification (UDI) applies to your devices, learn how to comply and get familiar with the Australian UDI Database (AusUDID).
-
Advertising permissionApproval under section 42DF for use of restricted representations by Molnlycke Health Care Pty Ltd
-
Advertising permissionApproval under section 42DF for use of restricted representations by Molnlycke Health Care Pty Ltd
-
GuidanceGuidance on the process for registering new medicines with new trade names that are 'clones' of currently registered prescription medicines
-
PageRead the latest news and information related to Unique Device Identification (UDI) in Australia.
-
GuidanceGuidance explaining the post-market surveillance of listed medicines and how we undertake compliance reviews.
-
Media releasesAustralia’s health leaders are increasingly concerned about the growing availability, promotion and use of unapproved peptide products in Australia.
-
PageInformation about the shortages of HRT products for patients and healthcare professionals
-
GuidanceGuidance on how to advertise health services that involve therapeutic goods, including how to comply with the Act and avoid prohibited advertising.
-
Compositional guidelinesCompositional Guideline: Lactococcus lactis subsp. lactis strain ATCC 19435 permitted for use in listed medicines.
-
Compositional guidelinesCompositional Guideline: Oxaceprol permitted for use in listed medicines.
-
Prescription medicine decision summarySlenyto has been approved for the treatment of insomnia in children and adolescents with neurogenetic disorders and/or attention-deficit hyperactivity disorder (ADHD).
-
PageLearn about the requirements for advertising therapeutic goods in specific circumstances, such as social media, and for specific types of products, like weight loss injections.
-
Media releasesWe have published new guidance on advertising restrictions for prescription medicines. This is to help individuals and businesses comply with Australia’s regulatory requirements.
-
News articlesListed medicine ingredients and requirements for their use have been updated in the Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 .
-
PageLearn which therapeutic goods can and cannot be advertised to the public.
-
Meeting statementsCommunique from the 5th meeting of the Human Research Ethics Committee and TGA Clinical Trials Discussion Forum,13 April 2026
-
PageSearch for infringement notices whereby a financial penalty may be issued in response to certain breaches of the Therapeutic Goods Act 1989 (the Act).
-
Advertising permissionApproval under section 42DF for use of restricted representations by Molnlycke Health Care Pty Ltd
-
Australian public assessment report (AusPar)Qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. The use of this vaccine should be in accordance with official recommendations.
-
Media releasesWe have issued 5 infringement notices totalling $19,800 to a health practitioner and an individual for the alleged unlawful importation of unapproved cosmetic injectables.
-
Prescription medicine decision summaryHibruka (orelabrutinib) has provisional approval in Australia for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
-
User guideA step-by-step guide to completing the form
-
Australian public assessment report (AusPar)Zynlonta (loncastuximab tesirine) has been provisionally approved as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
-
Australian public assessment report (AusPar)Niktimvo (axatilimab) has been approved for the treatment of chronic graft-versus host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and paediatric patients 6 years and older.